Literature DB >> 17277727

The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.

Jiri Heracek1, Michael Urban, Jana Sachova, Jitka Kuncova, Vaclav Eis, Vaclav Mandys, Richard Hampl, Luboslav Starka.   

Abstract

OBJECTIVE: Prostate cancer is now recognized as one of the principal medical problems facing male population and the commonest cancer in males in delevoped countries. The aim of this study was to find out whether serum hormone levels differ significantly in localized (pT2) and locally advanced (pT3-pT4 or N1) prostate cancer.
METHODS: In 250 men (mean age+/-SEM: 63.8+/-0.4) who underwent radical retropubic prostatectomy for histologically confirmed prostate cancer were analyzed serum samples for total testosterone, dehydroepiandrosterone sulfate, estradiol, progesterone, prolactin, cortisol, sex hormone-binding globulin, luteinizing hormone and follicle stimulating hormone. Free testosterone content was calculated from total testosterone and SHBG concentrations.
RESULTS: Significantly lower serum level of FSH, i.e. 5.63+/-0.31 vs. 7.07+/-0.65 U/L was found in patients with localized prostate cancer than in locally advanced (p<0.05). Significant correlation was found between serum levels of DHEAS and cortisol in both groups (p<0.02), estradiol and prolactin in patients with locally advanced prostate cancer, as well between LH and prolactin (p<0.05). No differences were found in other observed hormones.
CONCLUSION: The results point to importance of hormone status as possible additional prognostic marker for patients with prostate cancer. Considerable research is needed to further understand influence of hormones on prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277727

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  10 in total

1.  Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Authors:  Andrea Salonia; Andrea Gallina; Firas Abdollah; Alberto Briganti; Umberto Capitanio; Nazareno Suardi; Matteo Ferrari; Marco Raber; Renzo Colombo; Massimo Freschi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2011-09-21       Impact factor: 4.226

2.  The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.

Authors:  Luis A Kluth; Shahrokh F Shariat; Christian Kratzik; Scott Tagawa; Guru Sonpavde; Malte Rieken; Douglas S Scherr; Karl Pummer
Journal:  World J Urol       Date:  2013-09-03       Impact factor: 4.226

3.  Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects.

Authors:  Jehonathan H Pinthus
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

4.  The Biochemical Effects of Silver Nanoparticles and Spirulina Extract on Experimentally Induced Prostatic Cancer in Rats.

Authors:  Afaf D Abd El-Magid; Omnia M AbdEl-Hamid; M A Younes
Journal:  Biol Trace Elem Res       Date:  2022-06-11       Impact factor: 4.081

5.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

6.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

7.  Experience with degarelix in the treatment of prostate cancer.

Authors:  Neal D Shore
Journal:  Ther Adv Urol       Date:  2013-02

8.  Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.

Authors:  Peter Iversen; Jan-Erik Damber; Anders Malmberg; Bo-Eric Persson; Laurence Klotz
Journal:  Ther Adv Urol       Date:  2015-12-16

9.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

10.  Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Authors:  Kassim Kourbanhoussen; France-Hélène Joncas; Christopher J D Wallis; Hélène Hovington; François Dagenais; Yves Fradet; Chantal Guillemette; Louis Lacombe; Paul Toren
Journal:  Asian J Androl       Date:  2022 Jan-Feb       Impact factor: 3.285

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.